Radyus Research

We continue on our mission to build a network of trusted drug development partners across the globe and support biotech companies from #Asia. ? Today marks a significant milestone with the announcement of our strategic partnership with Dt&CRO, a distinguished CRO headquartered in #SouthKorea. ? Mr. Chaegyu Park, CEO of Dt&CRO, expressed his excitement, highlighting the partnership's potential to facilitate the entry of Korean biotech companies into the U.S. market.?"By combining our expertise in laboratory testing with Radyus Research's comprehensive support for drug development and regulatory strategy, we can offer a holistic solution that meets the needs of biotech innovators in South Korea and enhances our global CRO competitiveness." ? Learn more about the partnership below! #drugdevelopment #partnership

?? Today, Radyus honors and supports #RareDiseaseDay! #RareDiseaseDay is a reminder of the challenges those living with rare diseases face and the need for better access to care. At Radyus Research, we’re proud to support biotech pioneers working on groundbreaking therapies that bring hope to these patient populations. Together, through awareness and action, we can make a difference! ???? And to learn more about how Radyus Research can help you achieve your drug development goals, schedule some time to chat with Kamyra Edokpolor, Ph.D. ??? ? #RareDiseaseDay #Biotech #Biopharma #RareDiseases #PatientCare #RadyusResearch #GlobalHealth #DrugDevelopmentOrganization #Planning #Execution

After laying off hundreds of regulatory scientists earlier this week, the FDA is now reaching out to former employees to return! ? This strategic decision aims to balance the need for skilled professionals with staffing cuts, ensuring the continuity of critical regulatory reviews to protect public health and safety. This unexpected shift highlights the uncertainty it creates in the biotech landscape. ? At Radyus Research, we recognize how complex the regulatory landscape can be for biotechs seeking IND approval. Our fully integrated approach which includes both strategic planning and tactical execution, allows us to work hand-in-hand with biotech leaders to support the development of groundbreaking, safe, and effective therapies, ensuring patient safety remains a top priority. ? Connect with Kamyra Edokpolor, Ph.D., to explore how we can ensure better drug development outcomes! ? Source: @Reuters ? #FDA #FDAChallenges #BiotechInnovation #Biopharma #RegulatoryLandscape #Drugdevelopmentpartner

Drug development requires precision, speed, and strategy. Each step presents unique challenges, but with an expert partner, you can navigate them with confidence. ? As your fully integrated drug development partner, we deliver a holistic approach. Our deep scientific expertise paired with operational execution and regulatory insight accelerate your drug development process. From optimizing lead compounds, streamlining pre-clinical studies, or preparing for clinical trials, our tailored solutions ensure your program stays on track through uncertain regulatory environments. ? With experience supporting over 50 clients across 12 countries, we help biotech innovators transform ideas into real therapeutic breakthroughs. ? Connect with Kamyra Edokpolor, Ph.D. to learn more about how Radyus Research can help you discover new pathways forward. ? #Biotech #PharmaInnovation #ClinicalResearch #BiotechStartups #R&D

Recent FDA layoffs have triggered a surge of uncertainty across the biopharma and medtech industries. With potentially fewer experts handling complex regulatory reviews, the industry now faces delays that could impact drug development timelines, and overall innovation. These layoffs aren't just about numbers—they represent real people who have dedicated their careers to ensuring the safety and efficacy of life-changing therapeutics. As timelines tighten, Radyus Research continues to provide expert guidance to small and midsize biotech companies, ensuring our clients can efficiently navigate the evolving regulatory landscape. We are in constant communication with our FDA contacts to bring you the most updated and relevant insights. Now more than ever, strategic regulatory support is essential to maintaining progress in drug development, both globally and in the US. Connect with Kamyra Edokpolor, Ph.D. to learn how Radyus can support your goals. #RegulatoryAffairs #FDA #PolicyChanges #FutureofBiotech #HealthcareRegulation

?? Navigating Drug Development with Confidence In biotech, the right plan isn’t just a roadmap—it’s the difference between success and setback. At Radyus Research, we partner with biotech companies and venture firms to de-risk drug development with structured, milestone-driven execution. ?? Expert-Led Strategy | Our seasoned team brings deep pharma R&D, commercialization, and venture capital experience. ?? Execution That Delivers | Acting as an extension of operating R&D teams, we tailor tactical plans to meet program objectives. Whether you're launching a new program or optimizing your current strategy, Radyus is your trusted partner from lab to clinic. Connect with Kamyra Edokpolor, Ph.D. to learn more about how Radyus Research can support you! #Biotech #DrugDevelopment #VentureCapital #Pharma #Startups

For small biotech companies, navigating the drug development landscape requires strategic planning and a clear understanding of your target product. But did you know different types of product profiles can help you along the way? ?? Understanding these distinctions is crucial for maximizing your resources and increasing your chances of success. Let's break down a few key profiles outside of the standard Target Product Profile (TPP): Preferred Product Characteristics (PPC): Think of this as your aspirational TPP. ? Used in early research, it describes the ideal characteristics, even if they aren't all immediately achievable. ?? Target Regimen Profile (TRP): Crucial for combination therapies! ? This profile defines the desired characteristics of the entire treatment regimen, not just a single drug. ?? Ideal Customer Profile (ICP): Know your audience! ?? This defines your perfect customer – their demographics, needs, and pain points. Essential for targeted marketing and commercial success. ?? User Profile: Focus on the end-user! ?? Whether it's a patient or healthcare professional, this profile describes their needs and how they'll interact with your product. Critical for user-centered design. ?? Which profile is right for you? It depends on your stage of development and goals. Connect with Kamyra Edokpolor, Ph.D. to discuss how the right product profile can accelerate your journey! ?? #biotech #drugdevelopment #productprofile #TPP #pharmaceuticals #strategy

Developing a new drug is a complex journey, especially for small biotech companies. One crucial tool that can significantly increase your chances of success is a Target Product Profile (TPP). Swipe through to learn why TPPs are so important and how they can benefit your drug development process. A strong TPP is your secret weapon in the competitive biotech landscape. Don't navigate the drug development process without one! Let us help you create a TPP that aligns with your goals and maximizes your potential. Connect with Kamyra Edokpolor, Ph.D. to learn more. #biotech #drugdevelopment #TPP #pharmaceuticals #innovation

At Radyus Research, we believe that diversity fuels innovation—and nowhere is that more evident than in drug development. In past years, we highlighted historical figures who shaped medicine and science during #BlackHistoryMonth. This year, we’re celebrating the Black leaders in our industry today—scientists, entrepreneurs, and executives who are driving breakthroughs, leading companies, and shaping the future of biotech. From pioneering new therapies to advocating for greater health equity, these leaders are making an impact that will be felt for generations. We are proud to stand alongside them in our shared mission to advance science and improve patient lives. ???Dr. Kizzmekia S. Corbett-Helaire, PhD?– Immunologist who led the development of the Moderna COVID-19 vaccine. ???Dr. Tony Coles?– Chairman & CEO of Cerevel Therapeutics, former CEO of Yumanity Therapeutics, with a track record of leading biotech innovation. ???Dr. Patrice Matchaba, MD?– Former Global Head of Corporate Responsibility at Novartis, working to expand access to medicine and advance health equity. ???Dr. Valerie Montgomery Rice?– President & CEO of Morehouse School of Medicine, leading efforts to diversify the medical workforce and address healthcare disparities. ???Dr. Kevin Churchwell?– President & CEO of Boston Children's Hospital, driving innovation in pediatric healthcare and advocating for health equity. ?? Drs. Tiffany Whitlow and Del Smith, PhD – Founders of Acclinate, a CRO leveraging AI and community engagement to increase diversity in clinical trials. ?? Dr. R'Kes Starling, RPh, MBA – President & CEO of Reveles, innovating decentralized clinical trials to engage underserved communities and improve outcomes. Who are the Black professionals in drug development who inspire you today? Let’s celebrate them together. #BlackHistoryMonth #DiversityInSTEM #DrugDevelopment #BiotechLeadership

Struggling with fragmented preclinical and clinical development? Are timelines slipping and budgets ballooning? Radyus Research offers a fully integrated approach, streamlining your drug development process and saving you precious time and resources. Don't let your innovative therapies get bogged down. Discover how our expertise and key capabilities can accelerate your path to success Ready to elevate your drug development journey with Radyus? Connect with Kamyra Edokpolor, Ph.D. : https://lnkd.in/e3unxaH7 #drugdevelopment #leadoptimization #indicationselection #strategicplanning